Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2007-03-27
2007-03-27
Qazi, Sabiha (Department: 1616)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C514S179000, C514S182000, C514S169000, C514S170000, C552S525000, C552S539000, C552S575000, C552S632000, C552S639000, C552S641000, C552S515000
Reexamination Certificate
active
10281794
ABSTRACT:
Methods of using 7α,11β-dimethyl-17β-hydroxyestra-4,14-dien-3-one (III)and 17 esters thereof for various hormonal therapies, oral and parenteral dosage forms comprising these actives, and processes for their preparation.
REFERENCES:
patent: 3577410 (1971-05-01), Teller et al.
patent: 5855905 (1999-01-01), Oettel et al.
patent: 6313108 (2001-11-01), Loozen et al.
patent: 6492536 (2002-12-01), Bhatnagar et al.
patent: 6670352 (2003-12-01), Cook et al.
patent: 2119708 (1971-11-01), None
patent: 1341061 (1973-12-01), None
patent: 1341601 (1973-12-01), None
patent: WO 99/26962 (1999-06-01), None
Balasubramanian et al “Recent Developments in Cancer, Etc.” Annual Reports in Medicinal Chemistry, 33, 1998, Academic Press, San Diego, pp. 151-159.
Draeua et al “Section V. Topics in Biology”, Annual Reports in Medicinal Chemistfy, 31, 1996. Academic Press, San Diego, pp. 241-246.
Nieschlag et al., “Plasma Androgen Levels in Men After Oral Administration of Testosterone or Testosterone Undecanoate,” Acta Endocrinol, vol. 79, No. 2, pp. 366-374; 1975.
Tauber et al., “Absolute Bioavailability of Testosterone After Oral Administration of Testosterone-Undecanoate and Testosterone,” European Journal of Drug Metabolism and Pharmacokinetics, vol. 11, No. 2, pp. 145-150; 1986.
Davidson et al., “Increasing Circulating Androgens with Oral Testosterone Undecanoate in Eugonadal Men,” Chemical Abstracts + Indexes American Chemical Society, vol. 13, No. 107, p. 91; Sep. 28, 1987.
“The Merck Index, 11thEdition,”Merck&Co., Inc., 1989.
Monder et al., “Studies on the Metabolism of Testosterone Trans- 4-n-butylcyclohexanoic Acid in the Cynomolgus Monkey, Macaca fascicularis,” Journal of Steroid Biochemistry and Molecular Biology, vol. 50, No. 5-6, pp. 305-311; 1994.
Monder et al., “Metabolism of Testosterone trans- 4-n-butylcyclohexyl carboxylate, a high potency androgen, in rodents and primates: in vitro studies,” Journal of Endocrinology, vol. 140, No. 3, pp. 465-473; 1994.
Partsch et al., “Injectable Testosterone Undecanoate Has More Favourable Pharmacokinetics and Pharmacodynamics than Testosterone Enanthate,” European Journal of Endocrinology, vol. 132, No. 4, pp. 514-519; 1995.
“Rote Liste,”ECV Editio Cantor, 1996.
Zitzmann et al., “Hormone Substitution in Male Hypogonadism,”Molecular and Cellular Endocrinology, v. 161 No. 8, pp. 73-88, (Mar. 2000).
Segaloff, Albert and Gabbard, R. Bruce, “14-Dehydro-19-Nortestosterone and its 7α-methyl derivative,”Steroids22, 99-105 (1973).
Rasmusson, Gary H. and Arth, Glen E., “Selective Synthesis of 14-Dehydroestranes,”Steroids, 22, 107-111 (1973).
Acosta Carmie Kirk
Blye Richard P.
Kim Hyun K.
Rao Pemmaraju Narasimha
Leydig , Voit & Mayer, Ltd.
Qazi Sabiha
The United States of America as represented by the Department of
LandOfFree
Methods of making, using and pharmaceutical formulations... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of making, using and pharmaceutical formulations..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of making, using and pharmaceutical formulations... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3793113